A

Acer Therapeutics Inc
F:P6NA

Watchlist Manager
Acer Therapeutics Inc
F:P6NA
Watchlist
Price: 0.804 EUR
Market Cap: 28.8m EUR

Acer Therapeutics Inc
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Acer Therapeutics Inc
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
A
Acer Therapeutics Inc
F:P6NA
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Revenue
$92.1B
CAGR 3-Years
10%
CAGR 5-Years
3%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Revenue
$48B
CAGR 3-Years
1%
CAGR 5-Years
4%
CAGR 10-Years
11%
Pfizer Inc
NYSE:PFE
Revenue
$62.8B
CAGR 3-Years
-14%
CAGR 5-Years
9%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Revenue
$64.2B
CAGR 3-Years
3%
CAGR 5-Years
13%
CAGR 10-Years
5%
Eli Lilly and Co
NYSE:LLY
Revenue
$59.4B
CAGR 3-Years
27%
CAGR 5-Years
21%
CAGR 10-Years
12%
No Stocks Found

Acer Therapeutics Inc
Glance View

Market Cap
28.8m EUR
Industry
Pharmaceuticals

Acer Therapeutics, Inc. is a pharmaceutical company. The company is headquartered in Newton, Massachusetts and currently employs 35 full-time employees. The company went IPO on 2006-09-01. The Company’s pipeline includes four programs: ACER-001 (sodium phenylbutyrate), ACER-801 (osanetant), EDSIVO (celiprolol) and ACER-2820 (emetine). ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); ACER-801 (osanetant) for the treatment of induced vasomotor symptoms (iVMS); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; and ACER-2820 (emetine), a host-directed therapy against a variety of viruses, including cytomegalovirus, zika, dengue, ebola and COVID-19.

P6NA Intrinsic Value
Not Available
A

See Also

What is Acer Therapeutics Inc's Revenue?
Revenue
0 USD

Based on the financial report for Dec 31, 2022, Acer Therapeutics Inc's Revenue amounts to 0 USD.

Back to Top